• The ANeED study – ambroxol in new and early dementia with Lewy bodies (DLB): protocol for a phase IIa multicentre, randomised, double-blinded and placebo-controlled trial 

      Chwiszczuk, Luiza; Breitve, Monica Haraldseid; Kirsebom, Bjørn-Eivind; Selnes, Per; Fløvig, John Christian Jøraholmen; Knapskog, Anne Brita; Skogseth, Ragnhild Eide; Hubbers, Jessica; Holst-Larsen, Elin; Rongve, Arvid (Journal article; Peer reviewed, 2023-05-26)
      Background: Currently, there are no disease-modifying pharmacological treatment options for dementia with Lewy bodies (DLB). The hallmark of DLB is pathological alpha-synuclein (aS) deposition. There are growing amounts ...
    • Brain amyloid and vascular risk are related to distinct white matter hyperintensity patterns 

      Pålhaugen, Lene; Sudre, Carole H; Teceläo, Sandra Raquel Ramos; Nakling, Arne; Almdahl, Ina Selseth; Kalheim, Lisa Flem; Cardoso, M Jorge; Johnsen, Stein Harald; Rongve, Arvid; Aarsland, Dag; Bjørnerud, Atle; Selnes, Per; Fladby, Tormod (Journal article; Peer reviewed, 2020)
      White matter hyperintensities (WMHs) are associated with vascular risk and Alzheimer’s disease. In this study, we examined relations between WMH load and distribution, amyloid pathology and vascular risk in 339 controls ...
    • Genome-wide meta-analysis for Alzheimer’s disease cerebrospinal fluid biomarkers 

      Jansen, Iris E.; van der Lee, Sven J.; Gomez-Fonseca, Duber; de Rojas, Itziar; Dalmasso, Maria Carolina; Grenier-Boley, Benjamin; Athanasiu, Lavinia; Bahrami, Shahram; Bergh, Sverre; Djurovic, Srdjan; Fladby, Tormod; Jarholm, Jonas Alexander; Knapskog, Anne Brita; Pålhaugen, Lene; Saltvedt, Ingvild; Selbæk, Geir; Selnes, Per; Andreassen, Ole; Shadrin, Alexey; Skoog, Ingmar; Soininen, Hilkka; Tsolaki, Magda; Van Broeckhoven, Christine; Van Dongen, Jasper; van Swieten, John C.; Vandenberghe, Rik; Vidal, Jean-Sébastien; Visser, Pieter J.; Vogelgsang, Jonathan; Waern, Margda; Wagner, Michael; Wiltfang, Jens; Wittens, Mandy M.J.; Zetterberg, Henrik; Zulaica, Miren; van Duijn, Cornelia M.; Bjerke, Maria; Engelborghs, Sebastiaan; Jessen, Frank; Teunissen, Charlotte E.; Pastor, Pau; Hiltunen, Mikko; Ingelsson, Martin; Clarimón, Jordi; Sleegers, Kristel; Ruiz, Agustín; Ramirez, Alfredo; Cruchaga, Carlos; Lambert, Jean-Charles; van der Flier, Wiesje M. (Journal article; Peer reviewed, 2022)
      Amyloid-beta 42 (Aβ42) and phosphorylated tau (pTau) levels in cerebrospinal fluid (CSF) reflect core features of the pathogenesis of Alzheimer’s disease (AD) more directly than clinical diagnosis. Initiated by the European ...
    • Longitudinal cerebrospinal fluid measurements show glial hypo- and hyperactivation in predementia Alzheimer’s disease 

      Nordengen, Kaja; Kirsebom, Bjørn-Eivind Seljelid; Richter, Grit; Pålhaugen, Lene; Gisladottir, Berglind; Siafarikas, Nikias Ioannis; Nakling, Arne Exner; Rongve, Arvid; Bråthen, Geir; Grøntvedt, Gøril Rolfseng; Gonzalez, Fernando; Waterloo, Knut; Sharma, Kulbhushan; Karikari, Thomas; Vromen, Eleonora M.; Tijms, Betty M.; Visser, Pieter J.; Selnes, Per; Kramberger, Milicia G.; Winblad, Bengt; Blennow, Kaj; Fladby, Tormod (Journal article; Peer reviewed, 2023)
      Background Brain innate immune activation is associated with Alzheimer’s disease (AD), but degrees of activation may vary between disease stages. Thus, brain innate immune activation must be assessed in longitudinal ...